GlassScriptPhysician profile
Katherine R Carter
NPI 1255652590
$5,887.52
in general payments reported to CMS, 2019-2025
26 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $987 · 2022: $1,595 · 2023: $1,460 · 2024: $1,493 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,239 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.84 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $830.16 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $774.46 | 2021-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $748.57 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $555.41 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $419.73 | 2022-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $417.72 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $304.72 | 2021-2023 | |
| Esperion Therapeutics, INC. | $279.80 | 2021-2024 | Nexletol |
| Amgen INC. | $277.02 | 2022-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $217.79 | 2021-2025 | Farxiga |
| Irhythm Technologies, INC. | $152.53 | 2022-2024 | Zio Xt Patch, Zio Monitor, Zio At Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.49 | 2022-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $130.23 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.06 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $84.57 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $84.44 | 2023-2025 | Cardiomems, Diamondback Coronary |
| United Therapeutics Corporation | $79.85 | 2022-2023 | Tyvaso |
| Abiomed | $71.02 | 2023-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $42.26 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $32.63 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $31.78 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $30.19 | 2023-2024 | |
| W. L. Gore & Associates, INC. | $22.92 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Kestra Medical Technology Services, INC. | $22.59 | 2025 | Assure Wcd |
| Itamar Medical INC | $20.83 | 2025 | Watchpatone |
| Novo Nordisk INC | $14.75 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.